Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

旁观者效应 曲妥珠单抗 医学 癌症研究 药理学 乳腺癌 化学 癌症 内科学 免疫学
作者
Ting Zhang,Lingfeng You,Jianyan Xu,Junzhao Yin,Bolei Qu,Yuchang Mao,Beibei Fu,Dan Cao,Linda Zhao,Jun Feng,Min Hu,Feng He
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (8_Supplement): LB031-LB031 被引量:6
标识
DOI:10.1158/1538-7445.am2023-lb031
摘要

Abstract Current clinical HER2-targeting ADCs, especially T-DXd, have shown strong efficacy in HER2-expressing/mutant cancers, however, with adverse events such as hematologic toxicities and interstitial lung disease (ILD)/pneumonitis. Here we presented a potential best-in-class HER2-directed ADC, SHR-A1811, which was composed of trastuzumab, a stable and cleavable linker, and a novel topoisomerase I inhibitor payload (SHR9265). SHR9265 was a delicately selected exatecan derivative with a better liposolubility and cellular permeability: SHR9265 had a higher AlogP value than SHR7971, synthesized using published DXd structure (3.67 vs. 2.72). Consistently, SHR9265 showed ~5 times higher membrane permeability (PAMPA model) at pH5 and pH7.4. Cell killing activity of SHR9265 was ~3 times more potent than SHR7971. SHR-A1811 had a drug-to-antibody ratio (DAR) of 5.7, and showed HER2-dependent growth inhibition against various breast cancer and gastric cancer cell lines. In the bystander killing system, SHR-A1811 was able to kill both SK-BR-3 (HER2+) and MDA-MB-468 (HER2-) cells when co-cultured, with the IC50 on MDA-MB-468 of 0.28 nM. The in vitro efficacy of SHR-A1811 was comparable with anti-Her2-SHR9265 (DAR 7.5) and ADC1 (synthesized using T-DXd structure), and stronger than anti-Her2-SHR9265 (DAR 3.5). In SK-BR-3 (HER2 high), JIMT-1 (HER2 moderate) and capan-1 (HER2 low) xenograft models, SHR-A1811 treatment resulted in a dramatic and sustained inhibition of tumor growth. A significantly stronger antitumor activity was observed for SHR-A1811 than ADC1 under the same dosages. Moreover, SHR-A1811 showed good stability and improved safety profiles, presumably due to the proper steric hindrance which was purposely designed on the payload (SHR9265). Less than 2% of payload release was observed in human plasma after a 21-day incubation. The HNSTD of SHR-A1811 in cynomolgus monkeys was 40mpk with thymus as the main target organ. No death and lung lesions were observed at dose levels up to 70mpk for 42 days, while ADC1 led to one male cynomolgus monkey death on day 10 at 70mpk with multiple lung damages. These findings were consistent with safety profiles observed in a multi-center, dose-escalation phase I clinical trial (NCT0444620). Patients with different solid tumor types received initial intravenous doses of SHR-A1811 from 1 to 8.0 mg/kg. Only trace amount of free toxin was detected. The Cmax of payload was 3.85 ng/ml at 8mg/kg of SHR-A1811. The incidence of G2 ILD was < 2.5% and the treatment discontinuation rate was 5.1% across doses. In summary, with a highly permeable payload, optimized DAR, great potency and better clinical safety profiles, SHR-A1811 has demonstrated the best-in-class potential. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC (NCT05424835, NCT05482568, NCT04818333, NCT05349409). Citation Format: Ting Zhang, Lingfeng You, Jianyan Xu, Junzhao Yin, Bolei Qu, Yuchang Mao, Beibei Fu, Dan Cao, Linda Zhao, Jun Feng, Min Hu, Feng He. SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB031.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
qxz完成签到,获得积分10
刚刚
清秀的仙人掌完成签到,获得积分10
2秒前
RayLam完成签到,获得积分10
2秒前
3秒前
以韓完成签到 ,获得积分10
3秒前
imica完成签到 ,获得积分10
4秒前
Diamond完成签到 ,获得积分10
4秒前
可耐的问柳完成签到 ,获得积分10
5秒前
HH关注了科研通微信公众号
7秒前
兔子完成签到,获得积分10
7秒前
7秒前
xxx完成签到 ,获得积分10
9秒前
ash发布了新的文献求助10
10秒前
科研通AI5应助哭泣笑柳采纳,获得10
10秒前
倾听阳光完成签到 ,获得积分10
11秒前
iPhone7跑GWAS完成签到,获得积分10
11秒前
chinbaor完成签到,获得积分10
13秒前
怡然猎豹完成签到,获得积分10
14秒前
songvv发布了新的文献求助10
14秒前
ash完成签到,获得积分10
14秒前
18秒前
shezhinicheng完成签到,获得积分10
18秒前
桃花不用开了完成签到 ,获得积分10
19秒前
futong发布了新的文献求助10
21秒前
张瑞雪完成签到 ,获得积分10
24秒前
666完成签到,获得积分10
25秒前
大模型应助大橙子采纳,获得10
25秒前
maclogos发布了新的文献求助10
26秒前
李燕完成签到,获得积分10
26秒前
hahaha完成签到,获得积分10
27秒前
长长的名字完成签到 ,获得积分10
28秒前
离子电池完成签到,获得积分10
28秒前
futong完成签到,获得积分10
29秒前
量子星尘发布了新的文献求助10
31秒前
CooL完成签到 ,获得积分10
32秒前
科学家发布了新的文献求助10
32秒前
zhang26xian完成签到,获得积分10
35秒前
天真酒窝完成签到,获得积分10
37秒前
CodeCraft应助RC_Wang采纳,获得10
38秒前
流沙无言完成签到 ,获得积分10
38秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022